IOVA

Iovance Biotherapeutics, Inc.

7.99 USD
-0.02 (-0.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Iovance Biotherapeutics, Inc. stock is down -22.12% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 Jun 16:27 17 Jan, 2025 5.00 CALL 75 9187
17 Jun 16:30 20 Dec, 2024 8.00 CALL 10000 73
18 Jun 14:11 17 Jan, 2025 6.00 PUT 250 291
21 Jun 19:45 17 Jan, 2025 5.00 CALL 100 9441
21 Jun 19:45 17 Jan, 2025 5.00 CALL 101 9441
21 Jun 19:45 17 Jan, 2025 5.00 CALL 200 9441
21 Jun 19:45 17 Jan, 2025 5.00 CALL 192 9441
21 Jun 19:45 17 Jan, 2025 5.00 CALL 100 9441
21 Jun 19:45 17 Jan, 2025 5.00 CALL 200 9441
21 Jun 19:54 17 Jan, 2025 10.00 CALL 400 7566

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. focuses on developing and commercializing cancer immunotherapy products. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma. The company was incorporated in 2007 and is headquartered in San Carlos, California.

  • JP Morgan
    Thu Jun 20, 07:42
    buy
    confirm
  • HC Wainwright & Co.
    Mon Jun 3, 07:34
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 31, 12:41
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 24, 07:27
    buy
    confirm